The 2026 British Society for Rheumatology guidelines for the management of SLE

The 2026 British Society for Rheumatology (BSR) guideline for the management of systemic lupus erythematosus (SLE) was published in Rheumatology by Md Yusof et al. This guideline aims to provide comprehensive, evidence-based, patient-focused consensus recommendations for the treatment of SLE, from diagnosis to delivery of care, in the UK.

Key data: Overall, 102 recommendations were formulated to address diagnosis, monitoring, pharmacological and non-pharmacological management of SLE, treatment of organ-specific manifestations including lupus nephritis (LN) and cutaneous lupus erythematosus (CLE), and delivery of care within the UK National Health Service (NHS). The guideline emphasizes a multidisciplinary approach to SLE care, including early diagnosis with prompt referral to secondary or tertiary care; comprehensive assessment of disease manifestations, activity, and cognitive impairment; regular monitoring of disease activity, damage, and treatment-related toxicities using appropriate tools; treat-to-target (T2T) strategies; organ-specific and individualized treatment; and shared decision-making and patient education. It also provides research and audit recommendations to promote equitable access to care and improve health outcomes for people with SLE.

Key learning: The 2026 BSR guidelines provide actionable, whole life course recommendations for the treatment of lupus across manifestations, highlighting the importance of individualized, T2T approaches.